Jonathan R. Strosberg, MD, discusses the need to develop additional targeted therapies in hepatocellular carcinoma.
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the need to develop additional targeted therapies in hepatocellular carcinoma (HCC).
With the first-line combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) now established as a standard of care in HCC, an optimal second-line treatment is needed, Strosberg says.
In addition, tumor sequencing can be used to learn more about rarer subgroups of patients with HCC. Moreover, rather than treating patients based on tumor origin, novel targeted therapies can be used to target specific mutations. Ultimately, the field is hopeful that sequencing and gene expression data will allow for a more targeted and personalized treatment approach in HCC, Strosberg concludes.